PharmEasy, one of Mumbai’s leading health-tech unicorns, has taken a decisive financial step by raising ₹1,700 crore in a debt round. The capital will primarily be used to repay a costly Goldman Sachs loan, underscoring the company’s efforts to balance between aggressive expansion and financial discipline. This development reflects both the challenges and strategic pivots shaping PharmEasy’s journey in India’s digital healthcare ecosystem.
2021 – Thyrocare Acquisition
PharmEasy borrowed ₹2,200 crore from Kotak Mahindra Bank to acquire Thyrocare, marking a major push into diagnostics.
This debt was intended to be repaid with proceeds from an initial public offering (IPO), but the company was unable to launch its public listing.
May 2022 – Goldman Sachs Refinance
The company refinanced its Kotak loan with a ₹2,700 crore Goldman Sachs loan. However, this came at high interest and strict covenants.
June 2023 – Covenant Breach
PharmEasy breached some financial covenants on the Goldman Sachs loan but continued servicing repayments, avoiding default.
April 2024 – Valuation Haircut
The company raised ~$216 million in equity but faced a dramatic ~90% valuation cut, dropping from $5.6 billion to just ~$710 million.
September 2025 – Latest Debt Raise
PharmEasy issued 1,700 non-convertible debentures (NCDs) worth ₹10 lakh each to raise ₹1,700 crore.
360 One led with ₹1,231 crore
Micro Labs added ₹210 crore
MVS Ventures, Bennett Coleman, and Alkram Ventures contributed the rest
These funds will clear the Goldman Sachs loan, easing cash flow pressures.
Cost of Borrowing and Liquidity Pressure
PharmEasy’s repeated reliance on high-cost debt highlights its liquidity struggles. The new round may reduce immediate risks but interest obligations remain a concern.
Valuation Erosion
A ~90% drop in valuation signals investor caution. Growth projections and profitability timelines are under sharper scrutiny.
Leadership and Operational Shifts
With leadership churn and slower revenue growth, the company’s operational execution is under the spotlight. FY25 revenue remained flat at ~₹5664 crore, but losses narrowed by 105% (from ₹5211 crore in FY24 to ₹2533 crore in FY25), suggesting some progress in cost control.
High interest costs even after refinancing
Dependence on external funding to sustain operations
Flat revenue growth, which could offset progress in reducing losses
Retiring the Goldman Sachs loan could free up cash flow and improve margins.
If PharmEasy demonstrates growth in FY26, investor confidence may strengthen.
Likely shift towards conservative strategies, focusing on profitability and unit economics rather than rapid expansion.
PharmEasy’s latest ₹1,700 crore debt raise is more than a financial transaction — it represents a turning point. The company is moving from aggressive expansion to capital efficiency and disciplined operations. Whether this strategic pivot sparks a sustainable turnaround remains uncertain, but it is a critical step towards stabilizing India’s most prominent health-tech unicorn.
UnlistedZone is not a SEBI-registered Research Analyst or Investment Advisor. All information provided on our platform is strictly for educational and informational purposes. We do not offer investment advice or stock recommendations. Investors are advised to conduct their own due diligence or consult a SEBI-registered advisor. Investments in unlisted and pre-IPO shares are subject to market risks including illiquidity and volatility. UnlistedZone does not assure any returns or accept liability for investment outcomes based on this report.
